Unleashing the power of inhibitors of oncogenic kinases through BH3 mimetics.
about
IL-15 triggers an antiapoptotic pathway in human intraepithelial lymphocytes that is a potential new target in celiac disease-associated inflammation and lymphomagenesisHow cell death shapes cancerA common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer.Targeting anti-apoptotic Bcl-2 by AT-101 to increase radiation efficacy: data from in vitro and clinical pharmacokinetic studies in head and neck cancerWhere now for anti-EGF receptor therapies in colorectal cancer?Identification of novel molecular regulators of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in breast cancer cells by RNAi screening.APC(Cdc20) suppresses apoptosis through targeting Bim for ubiquitination and destruction.Ionizing radiation sensitizes breast cancer cells to Bcl-2 inhibitor, ABT-737, through regulating Mcl-1Cell deathPlatelet senescence and phosphatidylserine exposure.Cell and molecular determinants of in vivo efficacy of the BH3 mimetic ABT-263 against pediatric acute lymphoblastic leukemia xenograftsSelective induction of cell death in melanoma cell lines through targeting of Mcl-1 and A1.Treatment with the Bcl-xL inhibitor ABT-737 in combination with interferon α specifically targets JAK2V617F-positive polycythemia vera hematopoietic progenitor cellsMaximal killing of lymphoma cells by DNA damage-inducing therapy requires not only the p53 targets Puma and Noxa, but also BimOvercoming multiple drug resistance mechanisms in medulloblastoma.Inhibition of MCL-1 in breast cancer cells promotes cell death in vitro and in vivoCafestol overcomes ABT-737 resistance in Mcl-1-overexpressed renal carcinoma Caki cells through downregulation of Mcl-1 expression and upregulation of Bim expression.SCF(FBW7) regulates cellular apoptosis by targeting MCL1 for ubiquitylation and destructionBeyond cell death - antiapoptotic Bcl-2 proteins regulate migration and invasion of colorectal cancer cells in vitroThe essential role of evasion from cell death in cancer.Destruction of tumor vasculature and abated tumor growth upon VEGF blockade is driven by proapoptotic protein Bim in endothelial cells.A time to kill: targeting apoptosis in cancer.Identification of cis-acting elements and splicing factors involved in the regulation of BIM Pre-mRNA splicingMolecular correlates of platinum response in human high-grade serous ovarian cancer patient-derived xenograftsPharmacological blockade of Bcl-2, Bcl-x(L) and Bcl-w by the BH3 mimetic ABT-737 has only minor impact on tumour development in p53-deficient mice.Targeting Cdc20 as a novel cancer therapeutic strategy.Cancer and radiation therapy: current advances and future directions.BH3-only proteins in apoptosis at a glanceThe two faces of FBW7 in cancer drug resistance.Structure-Function Analysis of the Mcl-1 Protein Identifies a Novel Senescence-regulating Domain.The BCL-2 protein family, BH3-mimetics and cancer therapy.microRNA-10b Is Overexpressed and Critical for Cell Survival and Proliferation in MedulloblastomaVav3 collaborates with p190-BCR-ABL in lymphoid progenitor leukemogenesis, proliferation, and survival.Preclinical In Vitro, In Vivo, and Pharmacokinetic Evaluations of FLLL12 for the Prevention and Treatment of Head and Neck Cancers.Bcl-xL promotes metastasis independent of its anti-apoptotic activity.Effect of a Smac Mimetic (TL32711, Birinapant) on the Apoptotic Program and Apoptosis Biomarkers Examined with Validated Multiplex Immunoassays Fit for Clinical Use.A phase II trial of the BCL-2 homolog domain 3 mimetic AT-101 in combination with docetaxel for recurrent, locally advanced, or metastatic head and neck cancer.N-terminally cleaved Bcl-xL mediates ischemia-induced neuronal deathInhibition of MCL-1 enhances lapatinib toxicity and overcomes lapatinib resistance via BAK-dependent autophagy.Targeting DNA polymerase ß for therapeutic intervention.
P2860
Q24604346-373A0C03-2A62-40A9-A37C-E0C4A6A03603Q27021441-61742B5C-6308-497E-998A-96CBE101BB4DQ27851729-D19E88E4-6524-483A-AD0F-4FAB173B25D0Q30983828-808619DE-F9E8-4978-B738-3DE39E8B2619Q31038305-6D42006E-AF54-438B-B524-B4CC124F2AC4Q33739941-EC93AA35-8FA1-40CB-9333-6A2DC3E0EBE8Q33842900-CA431CE1-A784-4CB2-997D-B08F48D6C542Q33924886-2921940C-E362-4E1F-91CE-5D5F3C3CF18FQ34019760-F785F537-7206-4C03-B81C-23C48CBBFA13Q34065484-E00B0133-6E66-49BE-8C77-533F76FD5986Q34135333-BC04077A-18FC-42C4-9E07-B509287CDD4BQ34146431-27AEA14C-8271-496A-A9B7-F29715ABD07EQ34360366-5F8C7EC1-6BC3-4E22-BD72-2CCE1ADB317AQ34450473-799B916E-33D9-45E0-B1CB-B872B426FF31Q34500602-46978FFD-D5B6-40A1-9B82-D9D99BD91300Q34581860-5F6F03DA-8DC1-4DF2-9C7A-C478FC51971CQ34662207-CF9D950D-52CA-40D3-9BF6-FDA9EAFEEBF1Q34788849-FC865FF6-66CF-4DB1-ACC9-43C3876D6DCEQ35009440-4EEC6C0E-0B4B-41EF-9AEF-85D15C0A3312Q35083049-EDC0C925-FFBF-49B9-A3C9-5A94572099EBQ35102284-E4F30A72-F277-4A3F-A267-E6CD2984F352Q35138968-A1AAC466-FFF5-4E37-8D70-FFCB039EF151Q35151577-B07B9A46-0C95-4695-B39D-3EF483EAEEB1Q35448716-FB23FFD1-DBA5-4835-BDBF-EEADD8B3E709Q35678266-C1F64EE5-3AC5-4861-83A3-9962F9A5A769Q35688708-8A144DB0-6CDE-4943-B4B0-6A6DB68DB0C8Q35816527-3AB06BCD-97C2-4DD8-B732-394736A9D279Q35883875-160A8B16-5D74-4599-8922-3166E24B044CQ35999467-77795709-9424-4D97-8CD4-ABDDAAE82BB1Q36065226-9334495B-42DE-43F1-8C02-FD4A1AFDF5ADQ36067778-B53EDE33-E27D-4C33-8D55-D5CA221EA614Q36083620-78C21535-112E-4C0C-884D-73B00039772BQ36141909-2F19362D-40D6-457C-A963-0676A1F0C50FQ36446689-87DA4184-5524-488B-8187-298EC1BFF3B8Q36528864-90D54236-2711-4B96-BBD3-73A959FF4472Q36586167-26A32CAC-C39B-46C3-972E-04085E9CA222Q37284056-DBB183C8-3CE1-4D73-9919-66D5A53415B8Q37390204-98FF7411-608E-4147-9DB6-B3CE0EAF706EQ37460333-FFE19AE2-9A8E-4E9E-81EB-FCCF236C6DDCQ37489149-799392C9-C2D4-4613-B375-8A408BF99E7C
P2860
Unleashing the power of inhibitors of oncogenic kinases through BH3 mimetics.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 03 April 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Unleashing the power of inhibitors of oncogenic kinases through BH3 mimetics.
@en
Unleashing the power of inhibitors of oncogenic kinases through BH3 mimetics.
@nl
type
label
Unleashing the power of inhibitors of oncogenic kinases through BH3 mimetics.
@en
Unleashing the power of inhibitors of oncogenic kinases through BH3 mimetics.
@nl
prefLabel
Unleashing the power of inhibitors of oncogenic kinases through BH3 mimetics.
@en
Unleashing the power of inhibitors of oncogenic kinases through BH3 mimetics.
@nl
P356
P1476
Unleashing the power of inhibitors of oncogenic kinases through BH3 mimetics.
@en
P2093
Claire Harris
Clare L Scott
P2888
P304
P356
10.1038/NRC2615
P407
P577
2009-04-03T00:00:00Z
P6179
1023532012